Hims & Hers Options Surge as Novo Nordisk Pact Ignites Debate Over Valuation and Future Strategy

The immediate catalyst is clear. Shares of Hims & Hers Health surged 10.27% to close at $25.88 on Monday, with trading volume exploding to 108 million shares. This move followed news that Novo Nordisk dropped a patent infringement case, a development that removed a near-term overhang. Yet the stock's reaction, and the concurrent surge in options activity, points to a market weighing a more complex calculus.

The options market is signaling heightened speculative positioning. Total open interest in the stock climbed 7.7% to 1.2 million contracts, a level that sits well above its recent average. More telling is the activity in both directions: call open interest rose 7.3% while put open interest jumped 8.3% in the same period. This simultaneous buildup suggests traders are not just betting on a single directional move, but are actively establishing positions to hedge or speculate on volatility around the Novo Nordisk news and broader industry dynamics.

The central question the market is grappling with is whether this deal resolution is a net positive or merely a temporary reprieve. The stock's strong rally indicates optimism that regulatory pressure is easing. Yet the elevated options volume, particularly the significant put buildup, reveals underlying caution. Investors appear to be positioning for the long-term impact of a crowded GLP-1 drug market, where Hims & Hers' business model faces intense competition and pricing pressure. The options surge, therefore, frames the immediate event not as a definitive resolution, but as a catalyst that has amplified the debate over the stock's fundamental trajectory.

The Business Catalyst: A Deal with Teeth

The settlement resolves the immediate legal overhang but does so on terms that force a strategic pivot for Hims & Hers. The core mechanics are a clear reversal from last month. After announcing plans to sell a cheaper, off-brand Wegovy pill, Hims dropped its plan to offer the cheaper, off-brand version of Wegovy just days later, following FDA threats and legal pressure. The new deal is a direct response to that retreat, creating a new revenue stream while imposing a key concession.

Under the agreement, Hims gains a significant new channel: it will sell FDA-approved Ozempic and Wegovy pills through its platform. This is a high-margin opportunity, as these branded products command premium pricing. For Novo Nordisk, the deal is a strategic win, expanding its prescription reach through a major telehealth provider. CEO Mike Doustdar framed it as part of a broader push to boost prescriptions for Wegovy, the cornerstone of Novo's U.S. growth.

In return, Hims must stop advertising compounded versions of these drugs. The company will no longer advertise its copies of the Novo medicines and will reserve its compounding business for "rare cases where they're needed." This is a critical concession that addresses the regulatory pressure that forced the earlier retreat. It signals a formal shift away from Hims' previous model, which profited from selling copycat versions amid legal and regulatory uncertainty.

The deal, therefore, is a tactical resolution with teeth. It removes the lawsuit threat and opens a new, more compliant revenue stream. Yet it does not fully resolve Hims' core business model dilemma. The company is now locked into a partnership that requires it to stop promoting its most profitable, albeit legally gray, products. The market's reaction-shares soaring on the news-reflects the relief of removing a legal overhang and the potential upside of the new channel. But the setup is now more complex: Hims must navigate its new role as a branded distributor while its legacy compounding business faces a more constrained future.

Financial Impact and Valuation Pressure

The new revenue channel provides a tangible boost, but it must now meet sky-high expectations. The partnership to sell FDA-approved Ozempic and Wegovy pills opens a high-margin stream for Hims & Hers, directly addressing the regulatory overhang that forced a retreat from its cheaper, off-brand plans just days earlier. This is a clear tactical win, but the market's valuation already prices in a much more transformative story. With a forward P/E of 46.21, investors are demanding that this deal accelerate growth to levels that may be difficult to achieve.

The stock's path since the news highlights this tension. Shares surged as much as 56% in pre-market trading on Monday, reflecting initial euphoria. Yet they closed the session up only 10.27% to $25.88, a cooling that suggests early traders are taking profits or distributing shares. This pattern-sharp initial pop followed by consolidation-is a classic sign of a speculative rally meeting resistance at a valuation that still leaves the stock well below its 52-week high of $70.43. The market remains deeply skeptical about the long-term viability of Hims' core business model, even after this deal.

The bottom line is that the partnership is a necessary step, not a sufficient one. It provides a new, compliant revenue source and removes a legal threat, but it does not resolve the fundamental pressure from a crowded GLP-1 market where pricing and competition are intensifying. For the stock to re-rate meaningfully higher, Hims must demonstrate that this new channel can scale rapidly enough to justify its premium valuation. Until then, the elevated options activity and the stock's choppy move indicate that the market sees this as a catalyst for debate, not a definitive resolution.

Catalysts and Risks to Watch

The immediate setup is clear: a legal overhang is lifted, a new revenue channel opens, but the stock's premium valuation demands flawless execution. The path forward hinges on a few critical near-term events and factors that will determine if the current price is sustainable or a temporary rally.

First, watch for regulatory enforcement. The FDA's stance remains a key constraint. While Commissioner Makary welcomed Hims' commitment to stop mass advertising of compounded drugs, the agency has pledged to take "decisive steps" to restrict practices by compounding pharmacies. The market will be monitoring for any follow-up actions or guidance that could further limit Hims' legacy business, even as it sells the branded versions. This regulatory pressure is the shadow over the new partnership.

Second, the details of the Novo partnership must be scrutinized. The broad outline is set, but the financial terms will define the new revenue stream's size and quality. Investors need clarity on pricing, volume commitments, and marketing terms. How aggressively will Novo push its branded products through Hims' platform? What are the margins for Hims? These specifics will be critical in the coming weeks as the deal moves from announcement to implementation.

Finally, the next earnings report, estimated for May 4, 2026, is the ultimate test. This report must show that the new channel is translating into tangible financial results. Given the stock's forward P/E of 46.21, the market expects this partnership to accelerate growth and improve profitability quickly. Any shortfall in revenue contribution or margin expansion from the Novo deal could quickly deflate the current optimism.

The bottom line is that the catalyst has been delivered, but the work is just beginning. The stock's sustainability depends on Hims navigating a complex landscape of regulatory scrutiny, executing a new and critical partnership, and delivering financial results that justify its premium multiple. For now, the elevated options activity suggests the market is watching these developments closely.